Trial Profile
An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability When Receiving Abemaciclib for Patients With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 25 Jan 2024 Status changed from active, no longer recruiting to completed.
- 06 Oct 2023 This trial has been completed in Spain, according to an European Clinical Trials Database record.
- 27 Sep 2022 Results assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer published in the Breast Cancer Research and Treatment.